Concepts (300)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bilirubin | 23 | 2020 | 424 | 4.350 |
Why?
|
| Hepatitis | 3 | 2023 | 227 | 1.650 |
Why?
|
| Esophageal and Gastric Varices | 3 | 2022 | 207 | 1.540 |
Why?
|
| Hyperbilirubinemia | 3 | 2020 | 77 | 1.210 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 3 | 2017 | 707 | 1.130 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2015 | 534 | 0.980 |
Why?
|
| Liver Cirrhosis | 5 | 2023 | 1864 | 0.920 |
Why?
|
| Nail Diseases | 1 | 2021 | 51 | 0.800 |
Why?
|
| HIV Protease Inhibitors | 2 | 2020 | 430 | 0.790 |
Why?
|
| Nails | 1 | 2021 | 291 | 0.710 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2022 | 1129 | 0.610 |
Why?
|
| Lipid Bilayers | 5 | 2001 | 381 | 0.610 |
Why?
|
| Hepacivirus | 3 | 2018 | 1372 | 0.590 |
Why?
|
| Cell Movement | 3 | 2017 | 5212 | 0.500 |
Why?
|
| Receptors, LDL | 1 | 2017 | 475 | 0.490 |
Why?
|
| Conflict of Interest | 1 | 2018 | 542 | 0.450 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 1130 | 0.450 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2017 | 1155 | 0.440 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2015 | 561 | 0.410 |
Why?
|
| Liver | 13 | 2023 | 7470 | 0.400 |
Why?
|
| Antioxidants | 2 | 2017 | 1659 | 0.370 |
Why?
|
| Taurocholic Acid | 1 | 2010 | 43 | 0.370 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2002 | 96 | 0.370 |
Why?
|
| Hepatitis B, Chronic | 2 | 2006 | 393 | 0.360 |
Why?
|
| Genes, APC | 1 | 2010 | 159 | 0.350 |
Why?
|
| Up-Regulation | 2 | 2015 | 4211 | 0.340 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 2077 | 0.300 |
Why?
|
| Monocytes | 1 | 2017 | 2593 | 0.300 |
Why?
|
| Intestinal Neoplasms | 1 | 2010 | 319 | 0.300 |
Why?
|
| Giant Cells | 1 | 2008 | 187 | 0.300 |
Why?
|
| Colitis | 1 | 2015 | 1149 | 0.300 |
Why?
|
| Ammonia | 2 | 2007 | 239 | 0.300 |
Why?
|
| Carnitine | 1 | 2007 | 239 | 0.280 |
Why?
|
| Serum Albumin | 3 | 2000 | 674 | 0.280 |
Why?
|
| Liver Diseases | 2 | 2006 | 1252 | 0.280 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2008 | 141 | 0.270 |
Why?
|
| Hepatitis C | 3 | 2018 | 1582 | 0.270 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2017 | 1499 | 0.260 |
Why?
|
| Lamivudine | 2 | 2006 | 342 | 0.260 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2010 | 867 | 0.260 |
Why?
|
| Intracellular Membranes | 3 | 2002 | 390 | 0.250 |
Why?
|
| Methylprednisolone | 2 | 2021 | 388 | 0.250 |
Why?
|
| Fatty Acids | 3 | 2007 | 1806 | 0.240 |
Why?
|
| Phosphatidylcholines | 5 | 2001 | 411 | 0.220 |
Why?
|
| Rats, Gunn | 3 | 2010 | 11 | 0.220 |
Why?
|
| Leukocytes | 2 | 2015 | 2039 | 0.220 |
Why?
|
| Circoviridae | 1 | 2001 | 3 | 0.210 |
Why?
|
| Circoviridae Infections | 1 | 2001 | 5 | 0.210 |
Why?
|
| Hepatitis Viruses | 1 | 2001 | 17 | 0.210 |
Why?
|
| Indinavir | 1 | 2001 | 74 | 0.200 |
Why?
|
| Endotoxins | 1 | 2004 | 525 | 0.200 |
Why?
|
| Adenoma | 2 | 2010 | 2168 | 0.200 |
Why?
|
| Fluorescence | 2 | 2001 | 751 | 0.200 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2021 | 370 | 0.200 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 916 | 0.200 |
Why?
|
| Membrane Potentials | 1 | 2004 | 1135 | 0.200 |
Why?
|
| Malnutrition | 1 | 2007 | 625 | 0.190 |
Why?
|
| Stearic Acids | 1 | 2001 | 53 | 0.190 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2001 | 138 | 0.190 |
Why?
|
| Paracentesis | 1 | 2001 | 95 | 0.190 |
Why?
|
| Hepatitis B Vaccines | 1 | 2001 | 194 | 0.180 |
Why?
|
| Phospholipids | 2 | 2001 | 781 | 0.180 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2002 | 615 | 0.170 |
Why?
|
| Alanine Transaminase | 1 | 2021 | 592 | 0.170 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 15108 | 0.170 |
Why?
|
| Neoplasm Proteins | 2 | 2002 | 3691 | 0.160 |
Why?
|
| Ascites | 1 | 2001 | 344 | 0.160 |
Why?
|
| Rats | 11 | 2010 | 24265 | 0.160 |
Why?
|
| Brain Diseases | 1 | 2007 | 1554 | 0.160 |
Why?
|
| Apolipoproteins | 1 | 2000 | 315 | 0.160 |
Why?
|
| Biological Transport | 6 | 2002 | 2119 | 0.160 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2022 | 388 | 0.150 |
Why?
|
| Cholesterol | 4 | 2018 | 2895 | 0.150 |
Why?
|
| Bile Acids and Salts | 2 | 1996 | 353 | 0.150 |
Why?
|
| Lipid Metabolism | 2 | 2017 | 1887 | 0.150 |
Why?
|
| Kinetics | 7 | 2002 | 6474 | 0.140 |
Why?
|
| Glutathione Transferase | 2 | 1996 | 595 | 0.140 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2010 | 643 | 0.140 |
Why?
|
| Colorectal Neoplasms | 2 | 2006 | 6754 | 0.130 |
Why?
|
| Nitric Oxide | 1 | 2004 | 2128 | 0.130 |
Why?
|
| Antiviral Agents | 2 | 2018 | 2978 | 0.130 |
Why?
|
| Dextran Sulfate | 1 | 2015 | 236 | 0.130 |
Why?
|
| HIV Infections | 2 | 2020 | 16678 | 0.130 |
Why?
|
| Humans | 38 | 2023 | 742088 | 0.130 |
Why?
|
| Collagenases | 1 | 1995 | 228 | 0.130 |
Why?
|
| Interleukin-5 | 1 | 2015 | 273 | 0.130 |
Why?
|
| Cytotoxins | 1 | 2015 | 153 | 0.130 |
Why?
|
| Animals | 20 | 2017 | 168561 | 0.120 |
Why?
|
| Diffusion | 3 | 2002 | 832 | 0.120 |
Why?
|
| Protective Agents | 1 | 2015 | 156 | 0.120 |
Why?
|
| Biopsy | 2 | 2021 | 6756 | 0.120 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 923 | 0.120 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2001 | 1320 | 0.120 |
Why?
|
| Nitrates | 1 | 2015 | 265 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2004 | 8300 | 0.120 |
Why?
|
| Biological Transport, Active | 3 | 2001 | 349 | 0.110 |
Why?
|
| Neoplasms | 2 | 2021 | 21596 | 0.110 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2015 | 209 | 0.110 |
Why?
|
| Lipopolysaccharides | 2 | 2015 | 2211 | 0.110 |
Why?
|
| Carrier Proteins | 3 | 2002 | 5019 | 0.110 |
Why?
|
| Bone Density | 1 | 2006 | 3469 | 0.110 |
Why?
|
| Apoptosis | 2 | 2010 | 9715 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 2542 | 0.110 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 596 | 0.110 |
Why?
|
| Male | 21 | 2021 | 349538 | 0.110 |
Why?
|
| Cesarean Section | 1 | 2001 | 1363 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2023 | 77098 | 0.100 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2001 | 2552 | 0.100 |
Why?
|
| Mitochondria | 1 | 2004 | 3520 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 627 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 3862 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2001 | 2211 | 0.100 |
Why?
|
| Middle Aged | 13 | 2022 | 213127 | 0.100 |
Why?
|
| Cell Line | 3 | 2015 | 15994 | 0.090 |
Why?
|
| Models, Biological | 4 | 2002 | 9581 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2002 | 3461 | 0.090 |
Why?
|
| Genital Neoplasms, Female | 1 | 1995 | 516 | 0.090 |
Why?
|
| Liposomes | 3 | 2001 | 758 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 10943 | 0.090 |
Why?
|
| Serum Albumin, Bovine | 2 | 2001 | 324 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 6534 | 0.090 |
Why?
|
| Solubility | 2 | 2002 | 1083 | 0.090 |
Why?
|
| Pregnancy Complications | 1 | 2003 | 2861 | 0.090 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2002 | 301 | 0.090 |
Why?
|
| Mice | 5 | 2017 | 81045 | 0.090 |
Why?
|
| Aorta | 1 | 2017 | 2057 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2022 | 3861 | 0.080 |
Why?
|
| Lymphocytes | 1 | 2017 | 2614 | 0.080 |
Why?
|
| Vaccination | 1 | 2001 | 3256 | 0.080 |
Why?
|
| Intestinal Mucosa | 2 | 2015 | 3038 | 0.080 |
Why?
|
| Female | 15 | 2021 | 379592 | 0.080 |
Why?
|
| Prevalence | 2 | 2021 | 15194 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2015 | 21821 | 0.080 |
Why?
|
| Collagen | 1 | 2017 | 2684 | 0.080 |
Why?
|
| Cell Membrane | 5 | 2000 | 3744 | 0.080 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2007 | 19 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2001 | 4465 | 0.080 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1995 | 987 | 0.070 |
Why?
|
| Glycoproteins | 1 | 1995 | 2260 | 0.070 |
Why?
|
| Colon | 1 | 2015 | 1773 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2004 | 6347 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 2018 | 2117 | 0.070 |
Why?
|
| Multiple Sclerosis | 1 | 2001 | 3076 | 0.070 |
Why?
|
| Azathioprine | 1 | 2008 | 355 | 0.070 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2001 | 689 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2018 | 3740 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2017 | 23387 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 12344 | 0.070 |
Why?
|
| Hepatitis B e Antigens | 1 | 2006 | 133 | 0.070 |
Why?
|
| Logistic Models | 1 | 2020 | 13403 | 0.070 |
Why?
|
| Proteins | 1 | 2001 | 6096 | 0.070 |
Why?
|
| Microsomes, Liver | 2 | 1996 | 175 | 0.070 |
Why?
|
| Osteocalcin | 1 | 2006 | 273 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 3 | 2004 | 6313 | 0.060 |
Why?
|
| Jaundice | 1 | 2005 | 89 | 0.060 |
Why?
|
| Carrageenan | 1 | 2004 | 66 | 0.060 |
Why?
|
| Annexin A5 | 1 | 2004 | 103 | 0.060 |
Why?
|
| beta Catenin | 1 | 2010 | 1058 | 0.060 |
Why?
|
| Cytochromes c | 1 | 2004 | 180 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2000 | 4249 | 0.060 |
Why?
|
| Particle Size | 2 | 2001 | 1640 | 0.060 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2004 | 171 | 0.060 |
Why?
|
| Cytoprotection | 1 | 2004 | 210 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 329 | 0.060 |
Why?
|
| Ovalbumin | 1 | 2005 | 719 | 0.060 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2004 | 167 | 0.060 |
Why?
|
| Prednisone | 1 | 2008 | 1567 | 0.060 |
Why?
|
| Endotoxemia | 1 | 2004 | 206 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2023 | 53187 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 39004 | 0.050 |
Why?
|
| Hindlimb | 1 | 2004 | 505 | 0.050 |
Why?
|
| Hepatitis B virus | 1 | 2006 | 513 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2004 | 759 | 0.050 |
Why?
|
| Time Factors | 2 | 2020 | 40054 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2010 | 3913 | 0.050 |
Why?
|
| Potassium Iodide | 1 | 2001 | 13 | 0.050 |
Why?
|
| Melanoma | 1 | 2020 | 5462 | 0.050 |
Why?
|
| Thermodynamics | 2 | 1995 | 594 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2017 | 14554 | 0.050 |
Why?
|
| Chemistry, Physical | 1 | 2001 | 156 | 0.050 |
Why?
|
| Heme Oxygenase-1 | 1 | 2004 | 381 | 0.050 |
Why?
|
| Energy Transfer | 1 | 2001 | 109 | 0.050 |
Why?
|
| Cattle | 2 | 2000 | 3923 | 0.050 |
Why?
|
| Chemical Phenomena | 1 | 2001 | 517 | 0.050 |
Why?
|
| Caspases | 1 | 2004 | 928 | 0.050 |
Why?
|
| Glucuronosyltransferase | 1 | 2001 | 128 | 0.050 |
Why?
|
| Ligands | 2 | 2001 | 3293 | 0.050 |
Why?
|
| Apolipoproteins D | 1 | 2000 | 14 | 0.050 |
Why?
|
| Cholic Acid | 1 | 2000 | 34 | 0.050 |
Why?
|
| Pancreatitis | 1 | 2007 | 1090 | 0.050 |
Why?
|
| Eosinophilia | 1 | 2005 | 531 | 0.050 |
Why?
|
| Adenine | 1 | 2006 | 936 | 0.050 |
Why?
|
| Cytokines | 1 | 2015 | 7317 | 0.050 |
Why?
|
| Liver Function Tests | 1 | 2021 | 528 | 0.050 |
Why?
|
| Mathematics | 1 | 2001 | 727 | 0.050 |
Why?
|
| Spin Labels | 1 | 2001 | 332 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 13655 | 0.040 |
Why?
|
| Aged | 7 | 2020 | 162944 | 0.040 |
Why?
|
| Eating | 1 | 2006 | 1535 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2004 | 2295 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 11690 | 0.040 |
Why?
|
| Gastric Bypass | 1 | 2007 | 812 | 0.040 |
Why?
|
| Carbon Radioisotopes | 1 | 2000 | 592 | 0.040 |
Why?
|
| Adult | 9 | 2022 | 213712 | 0.040 |
Why?
|
| Models, Chemical | 1 | 2001 | 626 | 0.040 |
Why?
|
| Erythrocyte Membrane | 1 | 2000 | 442 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2004 | 3701 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2008 | 2107 | 0.040 |
Why?
|
| Fasting | 1 | 2004 | 1589 | 0.040 |
Why?
|
| Patient Simulation | 1 | 2001 | 308 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2001 | 1902 | 0.040 |
Why?
|
| United States | 2 | 2021 | 69693 | 0.040 |
Why?
|
| Emergencies | 1 | 2003 | 1164 | 0.040 |
Why?
|
| Plasma | 1 | 2000 | 575 | 0.040 |
Why?
|
| Health Surveys | 2 | 2004 | 4030 | 0.040 |
Why?
|
| Anemia, Myelophthisic | 1 | 1976 | 6 | 0.040 |
Why?
|
| Heart Failure | 1 | 2020 | 10856 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 11363 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2000 | 637 | 0.030 |
Why?
|
| Fibrosis | 1 | 2022 | 2026 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 914 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2002 | 9941 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2021 | 1608 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 1995 | 99 | 0.030 |
Why?
|
| Solutions | 2 | 1996 | 426 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 6483 | 0.030 |
Why?
|
| Subcellular Fractions | 1 | 1996 | 547 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2020 | 1961 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 4147 | 0.030 |
Why?
|
| Risk Factors | 3 | 2006 | 72145 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1995 | 347 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2010 | 10472 | 0.030 |
Why?
|
| Ion Transport | 1 | 1995 | 320 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 3800 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2001 | 1915 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 1847 | 0.030 |
Why?
|
| Sex Factors | 1 | 2006 | 10392 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 4455 | 0.030 |
Why?
|
| Buffers | 1 | 1992 | 147 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1996 | 2645 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 1995 | 638 | 0.030 |
Why?
|
| Weight Loss | 1 | 2023 | 2604 | 0.030 |
Why?
|
| Erythropoiesis | 1 | 1976 | 705 | 0.030 |
Why?
|
| Viscosity | 1 | 1992 | 328 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2001 | 2051 | 0.020 |
Why?
|
| Comorbidity | 1 | 2006 | 10372 | 0.020 |
Why?
|
| Erythropoietin | 1 | 1976 | 724 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 1992 | 683 | 0.020 |
Why?
|
| Membrane Lipids | 1 | 1992 | 248 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2006 | 9144 | 0.020 |
Why?
|
| Pregnancy | 2 | 2003 | 29087 | 0.020 |
Why?
|
| Microbial Collagenase | 1 | 1990 | 122 | 0.020 |
Why?
|
| Recurrence | 1 | 2002 | 8333 | 0.020 |
Why?
|
| Membrane Fusion | 1 | 1992 | 273 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2023 | 8297 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 7721 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2018 | 2205 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1994 | 3133 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 6171 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2001 | 5385 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 1976 | 2513 | 0.020 |
Why?
|
| Protein Binding | 1 | 2000 | 9387 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2020 | 4983 | 0.020 |
Why?
|
| Lung | 1 | 2005 | 9826 | 0.020 |
Why?
|
| Asthma | 1 | 2005 | 5955 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 9274 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1976 | 2941 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2023 | 62966 | 0.020 |
Why?
|
| Disease Progression | 1 | 2002 | 13256 | 0.020 |
Why?
|
| Adolescent | 3 | 2018 | 85649 | 0.020 |
Why?
|
| Inflammation | 1 | 2004 | 10578 | 0.020 |
Why?
|
| Survival Rate | 1 | 2018 | 12773 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 19862 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 23320 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2002 | 40955 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11472 | 0.010 |
Why?
|
| Incidence | 1 | 2018 | 20928 | 0.010 |
Why?
|
| Prognosis | 1 | 2020 | 29010 | 0.010 |
Why?
|
| Glycodeoxycholic Acid | 1 | 1996 | 23 | 0.010 |
Why?
|
| Taurodeoxycholic Acid | 1 | 1996 | 13 | 0.010 |
Why?
|
| Calorimetry | 1 | 1996 | 126 | 0.010 |
Why?
|
| Taurochenodeoxycholic Acid | 1 | 1996 | 34 | 0.010 |
Why?
|
| Demography | 1 | 2001 | 1650 | 0.010 |
Why?
|
| Micelles | 1 | 1996 | 203 | 0.010 |
Why?
|
| Scattering, Radiation | 1 | 1996 | 498 | 0.010 |
Why?
|
| Permeability | 1 | 1996 | 738 | 0.010 |
Why?
|
| Heme | 1 | 1976 | 307 | 0.010 |
Why?
|
| Urea | 1 | 1996 | 449 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1996 | 2255 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1990 | 5249 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 56350 | 0.010 |
Why?
|
| Microvilli | 1 | 1990 | 241 | 0.010 |
Why?
|
| Detergents | 1 | 1990 | 230 | 0.010 |
Why?
|
| Light | 1 | 1996 | 1374 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1990 | 549 | 0.010 |
Why?
|
| Iron | 1 | 1976 | 1773 | 0.000 |
Why?
|
| Immunoblotting | 1 | 1990 | 1683 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1990 | 2505 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2001 | 57683 | 0.000 |
Why?
|
| Child | 1 | 2001 | 77478 | 0.000 |
Why?
|
Concepts
(300)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(12)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_